The Motley Fool

Why the Paradigm Biopharmaceuticals share price has surged 11% higher

The Paradigm Biopharmaceuticals Ltd (ASX: PAR) share price has surged 11% higher to $1.40 in Friday afternoon trade.

The small-cap biotechnology company this morning announced a consistent reduction in pain from an additional 38 patients with osteoarthritis treated with injectable Pentosan Polysulfate Sodium (iPPS) under the Therapeutic Goods Administration Special Access Scheme.

Combined with a previously reported 145 patients, Paradigm reports that this brings the average reduction in pain scores to 51.4% across 183 patients.

Paradigm management advised that the pain-reducing effects of iPPS are considered significantly superior to the typical 15% pain reduction scores reported for opioid treatments for chronic pain in osteoarthritis of the knee and hip.

With a market capitalisation of $188 million, Paradigm Biopharmaceuticals is the 610th largest company quoted on the ASX.

The Paradigm Biopharmaceuticals share price has risen 438% in the last 12 months, while the S&P/ASX 200 Index has fallen roughly 4.97%. 

The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

NEW. Five Cheap and Good Stocks to Buy in 2019…

Our Motley Fool experts have just released a brand new FREE report, detailing 5 dirt cheap shares that you can buy today.

One stock is an Australian internet darling with a rock solid reputation and an exciting new business line that promises years (or even decades) of growth… while trading at an ultra-low price…

Another is a diversified conglomerate trading near a 52-week low all while offering a 2.8% fully franked yield…

Plus 3 more cheap bets that could position you to profit over the next 12 months!

See for yourself now. Simply click the link below to scoop up your FREE copy and discover all 5 shares. But you will want to hurry – this free report is available for a brief time only.